- Says drug worked for some COVID-19 patients
The National Agency for Food and Drug Administration and Control (NAFDAC has decided to carry on with the clinical trial of Hydroxychloroquine and Chloroquine as possible treatment of COVID-19 despite the decision of the World Health Organisation (WHO) to suspend the process.
The Director-General of the agency, Prof. Mojisola Adeyeye, in a chat with TVC Tuesday stated that the drugs have been effective in the treatment of COVID-19 patients at the emergent stage of the virus.
Adeyeye disclosed that there is data to prove that Hydroxychloroquine worked for many COVID-19 patients, hence, the decision to continue with the clinical trials in Nigeria.
She revealed that the potency of the drugs depends on the severity of the disease in the patient’s body
The NAFDAC boss expressed hope that the clinical trials should be concluded within four months if medical doctors, research scientists, pharmacists, herbal experts work together.
WHO Director-General, Dr. Tedros Ghebreyesus had earlier on announced that the Executive Group of the organisation has implemented a temporary pause of the Hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board.